Important Notice: Our web hosting provider recently started charging us for additional visits, which was unexpected. In response, we're seeking donations. Depending on the situation, we may explore different monetization options for our Community and Expert Contributors. It's crucial to provide more returns for their expertise and offer more Expert Validated Answers or AI Validated Answers. Learn more about our hosting issue here.

Can Peg-Interferon (IFN) α-2a Eradicate JAK2V617F-Positive Bone Marrow Progenitors in Polycythemia Vera (PV)?

April 26, 2017bone eradicate ifn marrow peg-interferon Polycythemia progenitors Vera

0

Posted

Can Peg-Interferon (IFN) α-2a Eradicate JAK2V617F-Positive Bone Marrow Progenitors in Polycythemia Vera (PV)?

2 Answers

0

Posted

Monday, December 8, 2008: 4:00 PM Gateway Ballroom 104 – South (Moscone Center) Jean-Jacques Kiladjian1*, Sabrina Dupont2*, Bruno Cassinat3*, Aline Mass2*, William Vainchenker2, Christine Chomienne4*, Franois Delhommeau5* and Pierre Fenaux11Hmatologie Clinique, Assistance Publique – Hpitaux de Paris, Hpital Avicenne; Paris 13 University, Bobigny, France 2INSERM U790, Institut Gustave Roussy, Villejuif, France 3Unit de Biologie Cellulaire, Assistance Publique – Hpitaux de Paris, Hpital Saint-Louis, Paris, France 4Institut Universitaire d’Hematologie, Inserm U718, Paris, France 5Laboratoire d’Hmatologie, Assistance Publique – Hpitaux de Paris, Hpital Saint-Antoine; Universit Paris 6 Pierre et Marie Curie, Paris, France Background: In a phase 2 trial of peg-IFN-alpha-2a, we observed disappearance of JAK2V617F in peripheral blood (PB) granulocytes in 7/29 (24%) treated PV patients using an allele specific PCR assay with a 1% sensitivity (Blood online, July 23, 2008). IFN-alpha has been sho

0

Posted

Oral and Poster Abstracts Oral Session: Myeloproliferative Disorders-Clinical Trials Monday, December 8, 2008: 4:00 PM Gateway Ballroom 104 – South (Moscone Center) Jean-Jacques Kiladjian1*, Sabrina Dupont2*, Bruno Cassinat3*, Aline Mass2*, William Vainchenker, MD, PhD4, Christine Chomienne5*, Franois Delhommeau6* and Pierre Fenaux11Hmatologie Clinique, Assistance Publique – Hpitaux de Paris, Hpital Avicenne; Paris 13 University, Bobigny, France 2INSERM U790, Institut Gustave Roussy, Villejuif, France 3Unit de Biologie Cellulaire, Assistance Publique – Hpitaux de Paris, Hpital Saint-Louis, Paris, France 4Institut Gustave Roussy, Villejuif, France 5Institut Universitaire d’Hematologie, Inserm U718, Paris, France 6Laboratoire d’Hmatologie, Assistance Publique – Hpitaux de Paris, Hpital Saint-Antoine; Universit Paris 6 Pierre et Marie Curie, Paris, France Background: In a phase 2 trial of peg-IFN-alpha-2a, we observed disappearance of JAK2V617F in peripheral blood (PB) granulocytes in 7/2